We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vaxon Biotech Successfully Completes its Phase I/II Trial of Vx-001 Cancer Vaccine
News

Vaxon Biotech Successfully Completes its Phase I/II Trial of Vx-001 Cancer Vaccine

Vaxon Biotech Successfully Completes its Phase I/II Trial of Vx-001 Cancer Vaccine
News

Vaxon Biotech Successfully Completes its Phase I/II Trial of Vx-001 Cancer Vaccine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vaxon Biotech Successfully Completes its Phase I/II Trial of Vx-001 Cancer Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vaxon Biotech, a specialist in tumor immunotherapy, announces today the successful conclusion of the Phase I/II trial of its Vx-001 therapeutic cancer vaccine.

As a result, Vaxon is pursuing the clinical development of Vx-001 by launching a pivotal phase III trial in non-small cell lung cancer (NSCLC) in 2010, and in hepatocellular carcinoma and breast cancer in 2012-2013.

The phase I/II trial was conducted among 116 patients with different types of cancer including 33 patients with NSCLC. The primary objective was to evaluate safety of Vx-001, with a secondary objective to evaluate immune response and clinical response.

Results showed that Vx-001 is safe (only grade I vaccine related toxicity was observed) and well tolerated by the patients, that it induces a long lasting vaccine specific immune response in 70 percent of patients, and that it has a significant clinical activity: four patients experienced objective response and 33 patients stabilized their disease for more than six months.

Survival of vaccinated patients was related to the immune response; patients who developed immune response had a longer survival than patients who failed to do so. Analysis focused on the thirty-three NSCLC showed that Vx-001 induces long lasting disease control, including objective responses, in more than 42 percent of patients. Survival of NSCLC vaccinated with Vx-001 was close to 19 months, at least 50 percent longer than normal in this patient population.

On the basis of this successful phase I/II trial and the very promising results in NSCLC, the European Medicines Agency (EMA) has approved the design of the planned pivotal phase III study and agreed to consider Vx-001 for marketing authorization after the completion of this trial.
Advertisement